- Home
- WDI vs CDMO Comparison
WDI vs CDMO Comparison
Compare WDI & CDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDI
- CDMO
- Stock Information
- Founded
- WDI 2021
- CDMO 1981
- Country
- WDI United States
- CDMO United States
- Employees
- WDI N/A
- CDMO N/A
- Industry
- WDI Trusts Except Educational Religious and Charitable
- CDMO Biotechnology: Pharmaceutical Preparations
- Sector
- WDI Finance
- CDMO Health Care
- Exchange
- WDI Nasdaq
- CDMO Nasdaq
- Market Cap
- WDI 786.7M
- CDMO 793.8M
- IPO Year
- WDI N/A
- CDMO N/A
- Fundamental
- Price
- WDI $14.87
- CDMO $12.46
- Analyst Decision
- WDI
- CDMO Hold
- Analyst Count
- WDI 0
- CDMO 3
- Target Price
- WDI N/A
- CDMO $12.25
- AVG Volume (30 Days)
- WDI 192.6K
- CDMO 1.3M
- Earning Date
- WDI 01-01-0001
- CDMO 12-10-2024
- Dividend Yield
- WDI 11.80%
- CDMO N/A
- EPS Growth
- WDI N/A
- CDMO N/A
- EPS
- WDI 1.12
- CDMO N/A
- Revenue
- WDI N/A
- CDMO $150,445,000.00
- Revenue This Year
- WDI N/A
- CDMO $19.05
- Revenue Next Year
- WDI N/A
- CDMO $20.88
- P/E Ratio
- WDI $12.82
- CDMO N/A
- Revenue Growth
- WDI N/A
- CDMO 6.75
- 52 Week Low
- WDI $12.16
- CDMO $5.90
- 52 Week High
- WDI $14.69
- CDMO $12.48
- Technical
- Relative Strength Index (RSI)
- WDI 62.72
- CDMO 66.88
- Support Level
- WDI $14.35
- CDMO $12.37
- Resistance Level
- WDI $14.58
- CDMO $12.45
- Average True Range (ATR)
- WDI 0.13
- CDMO 0.05
- MACD
- WDI 0.07
- CDMO -0.01
- Stochastic Oscillator
- WDI 98.70
- CDMO 100.00
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.
About CDMO Avid Bioservices Inc.
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.